Transplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth

Simple item page
dc.contributor.authorUtama, D.P.
dc.contributor.authorCrowther, C.A.
dc.date.issued2018
dc.description.abstractBackground: Despite major advances in medical technology, the incidence of preterm birth remains high. The use of antenatal corticosteroid administered transplacentally, by intramuscular injection to women at risk of preterm birth, has reduced the incidence of respiratory distress syndrome and increased the survival rates of preterm infants. However, this intervention also comes with its own risks and side eGects. Animal studies and early studies in pregnant women at risk of preterm birth have reported the use of an alternative route of administration, by direct intramuscular injection of corticosteroid into the fetus under ultrasound guidance, in an attempt to minimise the side-eGect profile.Directfetal corticosteroid administration may have benefits over maternal administration in terms of safety and eGicacy. Objectives: To assess if diGerent routes of corticosteroid administration (maternal versus direct fetal) have eGects on health outcomes for women and their babies. Search methods We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (25 October 2017), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (25 October 2017) and reference lists of retrieved studies. Selection criteria Randomised controlled trials comparing maternal with direct fetal routes of antenatal corticosteroid administration in women at risk of preterm birth. Data collection and analysis: The two review authors independently assessed study eligibility. In future updates of this review, at least two review authors will extract data and assess the risks of bias in included studies. We will also assess the quality of the evidence using the GRADE approach. Main results: We did not identify any eligible randomised controlled trials to include in this review.
dc.description.statementofresponsibilityDebby P Utama, Caroline A Crowther
dc.identifier.citationCochrane Database of Systematic Reviews, 2018; 2018(6):CD008981-CD008981
dc.identifier.doi10.1002/14651858.CD008981.pub3
dc.identifier.issn1469-493X
dc.identifier.issn1469-493X
dc.identifier.orcidCrowther, C.A. [0000-0002-9079-4451]
dc.identifier.urihttps://hdl.handle.net/2440/134128
dc.language.isoen
dc.publisherWiley
dc.relation.grantNHMRC
dc.rights© 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
dc.source.urihttps://doi.org/10.1002/14651858.cd008981.pub3
dc.subjectAdrenal Cortex Hormones [*administration & dosage]; Fetal Organ Maturity [*drug effects]; Fetus; Injections [methods]; Injections, Intramuscular [methods]; Lung [*embryology]; Placenta; Premature Birth; Risk; Female; Humans; Pregnancy
dc.subject.meshLung
dc.subject.meshFetus
dc.subject.meshPlacenta
dc.subject.meshHumans
dc.subject.meshPremature Birth
dc.subject.meshAdrenal Cortex Hormones
dc.subject.meshInjections
dc.subject.meshInjections, Intramuscular
dc.subject.meshRisk
dc.subject.meshFetal Organ Maturity
dc.subject.meshPregnancy
dc.subject.meshFemale
dc.titleTransplacental versus direct fetal corticosteroid treatment for accelerating fetal lung maturation where there is a risk of preterm birth
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Paediatrics publications